Discover 3,498 paid clinical trials in Torrance, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,498
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
for
Advanced Melanoma
Location: Santa Monica CA, Los Angeles CA, La Jolla CA, Tucson AZ,
Sponsor: Immunocore Ltd
Sex: All
Age: 18+
Code: NCT06112314
Phase 3, Recruiting
Comparative Evaluation of A-CP HA Kit, Hyaluronic Acid and Placebo for the Treatment of Knee Osteoarthritis
for
Knee Osteoarthritis
Location: Santa Monica CA
Sponsor: Regen Lab SA
Sex: All
Age: 50 - 70+
Code: NCT03201614
Recruiting
A Study of ASP3082 in Adults With Advanced Solid Tumors
for
Solid Tumor
Location: Santa Monica CA, Duarte CA, Portland OR, Denver CO,
Sponsor: Astellas Pharma Inc
Sex: All
Age: 18+
Code: NCT05382559
Phase 1, Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
for
Carcinoma, Non-Small Cell Lung,
Location: Santa Monica CA, Los Angeles CA, Fullerton CA,
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Sex: All
Age: 18+
Code: NCT04389632
Phase 1, Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
for
Carcinoma, Non-Small-Cell Lung
Location: Los Angeles CA, Orange CA, Oceanside CA, San Diego CA,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06890598
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Location: Los Angeles CA, Las Vegas NV, Walnut Creek CA,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06119581
Phase 3, Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
for
Metabolic Dysfunction-Associated Steatohepatitis,
Location: Pasadena CA, Rialto CA, Lancaster CA, Santa Maria CA,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18 - 70+
Code: NCT06920043
Phase 2, Recruiting
Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting ("DINOSAur II")
for
Stage III Solid Tumors, Stage IV Solid Tumors
Location: Glendale CA
Sponsor: Glendale Adventist Medical Center d/b/a Adventist Health Glendale
Sex: All
Age: 18+
Code: NCT05703243
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
for
Gaucher Disease, Cerebroside Lipidosis Syndrome,
Location: Beverly Hills CA, Los Angeles CA, Orange CA, Irvine CA,
Sponsor: Genzyme, a Sanofi Company
Sex: All
Age: 0+
Code: NCT00358943
Recruiting
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
for
Refractory Rheumatoid Arthritis (RA),
Location: Los Alamitos CA, Los Angeles CA, Santa Ana CA,
Sponsor: Artiva Biotherapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06991114
Phase 2, Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
for
Advanced HR+/HER2- Breast Cancer,
Location: Los Angeles CA, Seattle WA, Houston TX, St Louis MO,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT06726148
Phase 1, Phase 2, Recruiting
A Biobehavioral Intervention for Young Men With Testicular Cancer
for
Testis Cancer
Location: Irvine CA, New York NY
Sponsor: University of California, Irvine
Sex: Male
Age: 18 - 39
Code: NCT04150848
Phase 2, Recruiting
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment